Harlan Robert, Zhang Hui
Department of Pathology, Johns Hopkins University, Baltimore, MD 21231, USA.
Expert Rev Proteomics. 2014 Dec;11(6):657-61. doi: 10.1586/14789450.2014.976558. Epub 2014 Oct 28.
New technologies in mass spectrometry are beginning to mature and show unique advantages for the identification and quantitation of proteins. In recent years, one of the significant goals of clinical proteomics has been to identify biomarkers that can be used for clinical diagnosis. As technology has progressed, the list of potential biomarkers has grown. However, the verification and validation of these potential biomarkers is increasingly challenging and require high-throughput quantitative assays, targeting specific candidates. Targeted proteomics bridges the gap between biomarker discovery and the development of clinically applicable biomarker assays.
质谱新技术正开始走向成熟，并在蛋白质鉴定和定量方面展现出独特优势。近年来，临床蛋白质组学的一个重要目标是识别可用于临床诊断的生物标志物。随着技术的进步，潜在生物标志物的清单不断增加。然而，对这些潜在生物标志物的验证和确认越来越具有挑战性，需要针对特定候选物的高通量定量分析。靶向蛋白质组学填补了生物标志物发现与临床适用生物标志物检测方法开发之间的空白。
